No benefit of low dose apixaban following acute COVID-19

AI nuclear energy background, future innovation of disruptive technology

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

Cervical cancer burden remains high in many countries; scale-up needed to meet 2030 elimination target

Previous article

Research reveals that a viral toxin may contribute to the severity of COVID-19

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News